Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2013 1
2015 4
2016 1
2017 1
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy.
Montfort A, Bertrand F, Rochotte J, Gilhodes J, Filleron T, Milhès J, Dufau C, Imbert C, Riond J, Tosolini M, Clarke CJ, Dufour F, Constantinescu AA, Junior NF, Garcia V, Record M, Cordelier P, Brousset P, Rochaix P, Silvente-Poirot S, Therville N, Andrieu-Abadie N, Levade T, Hannun YA, Benoist H, Meyer N, Micheau O, Colacios C, Ségui B. Montfort A, et al. Among authors: bertrand f. Cancer Immunol Res. 2021 May;9(5):568-582. doi: 10.1158/2326-6066.CIR-20-0342. Epub 2021 Mar 16. Cancer Immunol Res. 2021. PMID: 33727246 Free PMC article.
TNF-R1, an immune checkpoint in melanoma?
Bertrand F, Colacios C, Ségui B. Bertrand F, et al. Genes Cancer. 2015 Sep;6(9-10):369-70. doi: 10.18632/genesandcancer.81. Genes Cancer. 2015. PMID: 26622939 Free PMC article. No abstract available.
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.
Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, Rochaix P, Andrieu-Abadie N, Levade T, Meyer N, Colacios C, Ségui B. Bertrand F, et al. Nat Commun. 2017 Dec 22;8(1):2256. doi: 10.1038/s41467-017-02358-7. Nat Commun. 2017. PMID: 29273790 Free PMC article.
Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy.
Paillasse MR, Esquerré M, Bertrand FA, Poussereau-Pomié C, Pichery M, Visentin V, Gueguen-Dorbes G, Gaujarengues F, Barron P, Badet G, Briaux A, Ancey PB, Sibrac D, Erdociain E, Özcelik D, Meneyrol J, Martin V, Gomez-Brouchet A, Selves J, Rochaix P, Battistella M, Lebbé C, Delord JP, Dol-Gleizes F, Bono F, Blanc I, Alam A, Hunneyball I, Whittaker M, Fons P. Paillasse MR, et al. Among authors: bertrand fa. Cancer Res Commun. 2022 Nov 29;2(11):1504-1519. doi: 10.1158/2767-9764.CRC-22-0151. eCollection 2022 Nov. Cancer Res Commun. 2022. PMID: 36970050 Free PMC article.
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1.
Imbert C, Montfort A, Fraisse M, Marcheteau E, Gilhodes J, Martin E, Bertrand F, Marcellin M, Burlet-Schiltz O, Peredo AG, Garcia V, Carpentier S, Tartare-Deckert S, Brousset P, Rochaix P, Puisset F, Filleron T, Meyer N, Lamant L, Levade T, Ségui B, Andrieu-Abadie N, Colacios C. Imbert C, et al. Among authors: bertrand f. Nat Commun. 2020 Jan 23;11(1):437. doi: 10.1038/s41467-019-14218-7. Nat Commun. 2020. PMID: 31974367 Free PMC article.
In vivo Effects in Melanoma of ROCK Inhibition-Induced FasL Overexpression.
Teiti I, Florie B, Pich C, Gence R, Lajoie-Mazenc I, Rochaix P, Favre G, Tilkin-Mariamé AF. Teiti I, et al. Among authors: florie b. Front Oncol. 2015 Jul 14;5:156. doi: 10.3389/fonc.2015.00156. eCollection 2015. Front Oncol. 2015. PMID: 26236689 Free PMC article.
11 results